Dynorphin 1-17 biotransformation peptides: properties, challenges and solutions for future therapeutics development
R Ballouze, SM Salhimi, N Mohtar… - Future medicinal …, 2023 - Future Science
It is well established that endogenously produced dynorphin 1-17 (DYN 1-17) is susceptible
to enzymatic degradation, producing a variety of unique fragments in different tissue …
to enzymatic degradation, producing a variety of unique fragments in different tissue …
Dynorphin 1-17 biotransformation peptides: properties, challenges and solutions for future therapeutics development.
R Ballouze, SM Salhimi, N Mohtar… - Future Medicinal …, 2023 - europepmc.org
It is well established that endogenously produced dynorphin 1-17 (DYN 1-17) is susceptible
to enzymatic degradation, producing a variety of unique fragments in different tissue …
to enzymatic degradation, producing a variety of unique fragments in different tissue …
Dynorphin 1-17 biotransformation peptides: properties, challenges and solutions for future therapeutics development
R Ballouze, SM Salhimi, N Mohtar… - Future medicinal … - pubmed.ncbi.nlm.nih.gov
It is well established that endogenously produced dynorphin 1-17 (DYN 1-17) is susceptible
to enzymatic degradation, producing a variety of unique fragments in different tissue …
to enzymatic degradation, producing a variety of unique fragments in different tissue …